Spanish authorities have dismantled a network of illegal aesthetic clinics across four provinces, arresting nine individuals and seizing over 10,000 doses of botulinum toxin. The operation highlights the growing risk of unregulated aesthetic treatments using products sourced from illicit channels, a concern for international buyers and distributors in the medical aesthetics supply chain.
Operation details
The investigation, conducted between March 2025 and May 2026, began after suspicious packages were detected at Foronda Airport in Vitoria. Shipments, primarily from South Korea and Vietnam, contained unauthorized medicines and medical products, including Botox, hyaluronic acid, and diabetes drugs, some misused for weight loss. The products entered Spain without authorization and without proper cold chain maintenance, compromising safety and efficacy.
Arrests and seizures
Nine individuals were arrested in Vizcaya, Barcelona, Las Palmas, and Asturias. Police conducted raids in Bilbao, Basauri, Galdakano, Barakaldo, L'Hospitalet de Llobregat, Cornellá de Llobregat, Avilés, Carrizal, and Vecindario. Seized items included over 10,000 Botox doses, hyaluronic acid, diabetes medications, and more than €115,000 in cash, allegedly proceeds from illegal procedures.
Regulatory and channel signals
Among those arrested were both unlicensed practitioners and registered healthcare professionals, indicating that even credentialed individuals may engage in unauthorized practices. The products were distributed through unregulated channels and used in hair salons, unauthorized beauty centers, and private homes. This case underscores the need for strict oversight of product sourcing and administration in aesthetic medicine.
What buyers should watch
For overseas importers and distributors, this operation reinforces the importance of verifying product traceability and cold chain compliance. Products entering the EU without authorization, especially from non-EU sources like South Korea and Vietnam, pose legal and safety risks. Buyers should ensure their suppliers adhere to EU medical device and pharmaceutical regulations to avoid involvement in illicit networks.
Sourcing context
The case highlights the vulnerability of the supply chain to counterfeit or improperly handled aesthetic products. The use of diabetes drugs for weight loss in unregulated settings is a growing concern. Distributors and clinics should prioritize sourcing from authorized manufacturers and distributors with documented cold chain logistics and regulatory approvals to maintain product integrity and patient safety.
Source: Read the original report | Published: June 12, 2026